Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.
Satoshi YukiKentaro YamazakiYu SunakawaHiroya TaniguchiHideaki BandoManabu ShiozawaTomohiro NishinaHisateru YasuiYoshinori KagawaNaoki TakahashiTadamichi DendaTaito EsakiHiasto KawakamiHironaga SatakeAtsuo TakashimaNobuhisa MatsuhashiTakeshi KatoChiharu AsanoYukiko AbeShogo NomuraTakayuki YoshinoPublished in: Cancer medicine (2023)
Pretreatment plasma IL-8 and sVCAM-1 levels could be predictive biomarkers to distinguish BEV and anti-EGFR mAbs when combined with chemotherapy in the 1L treatment of RAS wild-type mCRC. Several plasma angiogenesis factors showed significant change at progression in 1L chemotherapy plus biologics for RAS wild-type mCRC, which are potential biomarkers for selecting an optimal angiogenesis inhibitor in second-line treatment.